T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion
Background T cell receptor (TCR)-engineered cells can be powerful tools in the treatment of malignancies. However, tumor resistance by Human Leukocyte antigen (HLA) class I downregulation can negatively impact the success of any TCR-mediated cell therapy. Allogeneic natural killer (NK) cells have de...
Saved in:
| Main Authors: | Miranda H Meeuwsen, Laura T Morton, Tassilo L A Wachsmann, Anne K Wouters, Dennis F G Remst, Marleen M van Loenen, J H Frederik Falkenburg, Mirjam H M Heemskerk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/3/e003715.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets
by: Marije A.J. de Rooij, et al.
Published: (2025-09-01) -
Integrated transcriptomics and machine learning reveal REN as a dual regulator of tumor stemness and NK cell evasion in Wilms tumor progression
by: Qingfei Cao, et al.
Published: (2025-06-01) -
NK cell activity in the tumor microenvironment
by: A. V. Kuznetsova, et al.
Published: (2025-05-01) -
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
by: Claudia Cantoni, et al.
Published: (2016-01-01) -
Recent advances in tumor immunotherapy based on NK cells
by: Mengmeng Chen, et al.
Published: (2025-08-01)